Drugs

OSIS Workshop: CDER Bioavailability/Bioequivalence Study Sites and Inspections of Good Laboratory Practice

Number of lessons: 9
FDA Regulatory Education for Industry (REdI) 2024 Conference – Plenary and Drugs Track

Number of lessons: 16
Statistical Considerations for Premarketing Risk Assessment

Number of lessons: 4
Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval

Number of lessons: 6
Facilitating Generic Drug Product Development through Product-Specific Guidances

Number of lessons: 10